COPD
Conditions
Interventions
Simvastatin group:Simvastatin tablets, 20 mg orally, once daily.
Control group:Conventional treatment was administered according to the relevant contents of the Guidelines for the Diagnosis and Management of Chronic Obstructive P
Sponsors
The Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary participation with signed informed consent; 2. Aged 40–80 years at the time of informed consent signing, either sex; 3. Current smokers or former smokers; 4. Patients with a prior diagnosis of COPD who are hospitalized due to acute exacerbation of COPD in respiratory or general internal medicine wards; 5. Hemodynamically stable within 24 hours of admission, with PaCO2 <= 70 mmHg; 6. No statin use for at least 6 months prior to enrollment.
Exclusion criteria
Exclusion criteria: 1. Patients with extremely severe condition requiring invasive mechanical ventilation; 2. Patients with other active pulmonary diseases prior to enrollment, such as active tuberculosis, lung cancer, pulmonary embolism, sarcoidosis, interstitial lung disease, primary pulmonary hypertension, and bronchial asthma; 3. Patients with severe hepatic or renal insufficiency, cardiac insufficiency, or other conditions requiring corresponding drug treatment; 4. Patients with unstable ischemic heart disease, myocardial infarction, or cerebrovascular accident within 6 months prior to enrollment, or those with acute coronary syndrome within 3 months, or who have undergone percutaneous coronary intervention or coronary artery bypass grafting; 5. Patients with psychiatric disorders, intellectual disability, poor motivation, drug or alcohol abuse, or other conditions that would limit participation in this study; 6. Participation in other clinical trials within 4 weeks prior to enrollment; 7. Women who are pregnant, breastfeeding, or planning to become pregnant during the study period, or women of childbearing potential not using effective contraception (urine HCG test required for women of childbearing age); 8. Patients receiving non-invasive or invasive mechanical ventilation that precludes oral medication administration; 9. Current use of macrolide antibiotics, azole antifungal agents, or amlodipine; 10. Patients with known hypersensitivity to simvastatin; 11. Patients on long-term statin therapy; 12. Patients deemed unsuitable for participation in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in COPD symptom assessment (mMRC, CAT scores), quality of life score differences (Saint George's Respiratory Questionnaire), and 6-minute walk test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood gas analysis parameters (PaO2, PaCO2, oxygenation index), changes in peak expiratory flow rate, changes in inflammatory markers (IL-17, IL-10, IL-8, IL-6, TNF-a, IFN-?, P-selectin, CRP), and drug safety indicators; | — |
Countries
China
Contacts
Public ContactXu Zhi
The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed